Video

Mark Cuban Cost Plus Drug Company confers savings on urologic drugs

Author(s):

Urology Times staff

“I would say that we did not anticipate the degree of potential cost savings,” says Ruchika Talwar, MD.

Current Time 0:00
Duration 3:54
Loaded: 4.20%
Stream Type LIVE
Remaining Time 3:54
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    In this video, Ruchika Talwar, MD, discusses the background and notable findings from the Journal of Urology paper, “Urologic Drug Price Stewardship – Potential Cost Savings Based on the Mark Cuban Cost Plus Drug Company Model.” Talwar is a urologic oncology fellow at Vanderbilt University Medical Center in Nashville, Tennessee.

    Related Videos
    De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment
    De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment
    Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
    Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
    Prostate cancer screening: Expert weighs in after Biden's diagnosis
    Prostate cancer screening: Expert weighs in after Biden's diagnosis
    1 expert in this video
    Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT
    1 expert in this video
    Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses
    Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
    Study results affirm effectiveness of evolving prostate cancer therapies
    Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
    Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
    Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
    Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
    Rebecca A. Campbell, MD, answers a question during a Zoom video interview
    Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
    1 expert in this video
    Comparing Trials Studying Treatment Intensification In mHSPC
    Related Content
    FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
    May 21st 2025

    FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC

    Hannah Clarke
    The application is seeking an expanded indication of talazoparib plus enzalutamide for mCRPC.
    Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause
    April 28th 2025

    Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause

    Melissa Kaufman, MD, PhD, FACS
    In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical management of this condition.
    Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC
    May 20th 2025

    Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC

    Hannah Clarke
    The phase 3 study design will now be submitted for final review by the agency.
    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
    April 27th 2025

    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

    Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
    Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
    SBRT may offer a safe alternative to CFRT after prostatectomy
    May 16th 2025

    SBRT may offer a safe alternative to CFRT after prostatectomy

    Hannah Clarke
    Data from the SCIMITAR trial showed that SBRT appeared safe and demonstrated comparable PROs compared with CFRT.
    Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI
    May 16th 2025

    Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI

    Melissa Kaufman, MD, PhD, FACS Hannah Clarke
    The CELLEBRATE trial is aiming to provide additional evidence to support the safety and efficacy of iltamiocel.
    © 2025 MJH Life Sciences

    All rights reserved.